Literature DB >> 9491825

How reproducible is bilateral forearm plethysmography?

J R Petrie1, S Ueda, A D Morris, L S Murray, H L Elliott, J M Connell.   

Abstract

AIMS: In studies using strain-gauge forearm plethysmography to measure changes in forearm blood flow (FBF) during intra-arterial infusions of vasoactive substances, measurements are often made in both arms simultaneously and the change in ratio of the infused and control arms used to express responses. However, the reproducibility of bilateral plethysmography in this setting has not been addressed in published studies. The unilateral technique remains in use, and forearm vascular resistance (FVR), an alternative method of expressing responses, is used by some investigators. We have assessed: (a) the intra-subject variability of bilateral FBF measurements (FBF ratios) at rest, after unilateral forearm exercise, and during intra-arterial infusions of vasoconstrictor substances; (b) whether bilateral plethysmography is more reproducible than unilateral plethysmography; and (c) the reproducibility of FVR (unilateral and bilateral).
METHODS: Study 1 Nine healthy subjects attended 3 study days, 1 week apart. FBF was measured at rest and after 2 min of standardized unilateral forearm exercise; between-day intra-subject variability was expressed as coefficients of variation (CV) calculated using two-way analysis of variance (ANOVA). Study 2 Five healthy subjects attended 2 study days when FBF was measured during incremental infusions of noradrenaline (15, 30, 150, 300 pmol min[-1]) and angiotensin II (1, 5, 10, 50 pmol min[-1]); for each individual subject at each dose intra-subject variability was assessed using the difference between responses (percentage change from baseline) on days 1 and 2.
RESULTS: Study 1 At rest, intra-subject variability (CV) of baseline FBF ratios was 19% compared with 31% (left) and 39% (right) for unilateral FBF measurements. After ipsilateral exercise, unilateral FBF measurements were more reproducible (32 vs 17%) than FBF ratios; by 20 min after exercise, the previous pattern had been re-established (19 vs 27%). Intra-subject variability (CV) of baseline FVR ratio and post-exercise FVR was 14%. Study 2 Inter-quartile ranges of the differences between responses on days 1 and 2 (FBF ratios vs FBF) were: angiotensin II 14 vs 18%; noradrenaline 16 vs 27%.
CONCLUSIONS: FBF ratios are more reproducible than unilateral FBF measurements at rest (CV 19% vs 39%) and for measuring responses to intra-arterial infusions of vasoconstrictor substances. FVR may have a small reproducibility advantage. Non-experimental stimuli can cause significant and misleading changes in measured responses if unilateral measurements are used; it is therefore recommended that responses to intra-arterial infusions should be measured using bilateral forearm plethysmography with the results expressed as FBF ratios.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491825      PMCID: PMC1873348          DOI: 10.1046/j.1365-2125.1998.00656.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Methods for the investigation of peripheral blood flow.

Authors:  A D GREENFIELD; R J WHITNEY; J F MOWBRAY
Journal:  Br Med Bull       Date:  1963-05       Impact factor: 4.291

2.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

3.  Variability and reproducibility of arterial and venous circulation parameters in the forearm and calf measured at one-week intervals.

Authors:  H U Altenkirch; G Koch; H E Koralewski
Journal:  Vasa       Date:  1990       Impact factor: 1.961

4.  Comparison of effects of locally infused angiotensin I and II on hand veins and forearm arteries in man: evidence for converting enzyme activity in limb vessels.

Authors:  J G Collier; B F Robinson
Journal:  Clin Sci Mol Med       Date:  1974-08

5.  Measuring forearm blood flow and interpreting the responses to drugs and mediators.

Authors:  N Benjamin; A Calver; J Collier; B Robinson; P Vallance; D Webb
Journal:  Hypertension       Date:  1995-05       Impact factor: 10.190

6.  Vascular structure enhances regional resistance responses in mild essential hypertension.

Authors:  B Egan; N Schork; R Panis; A Hinderliter
Journal:  J Hypertens       Date:  1988-01       Impact factor: 4.844

7.  Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.

Authors:  J R Cockcroft; D G Sciberras; M R Goldberg; J M Ritter
Journal:  J Cardiovasc Pharmacol       Date:  1993-10       Impact factor: 3.105

8.  Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal.

Authors:  A Calver; J Collier; S Moncada; P Vallance
Journal:  J Hypertens       Date:  1992-09       Impact factor: 4.844

9.  Preserved endothelium-dependent vasodilatation in patients with essential hypertension.

Authors:  J R Cockcroft; P J Chowienczyk; N Benjamin; J M Ritter
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

10.  Endothelin is a potent long-lasting vasoconstrictor in men.

Authors:  J G Clarke; N Benjamin; S W Larkin; D J Webb; G J Davies; A Maseri
Journal:  Am J Physiol       Date:  1989-12
View more
  24 in total

1.  Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement.

Authors:  H A Walker; G Jackson; J M Ritter; P J Chowienczyk
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 2.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

3.  Responses to endothelin-1 in patients with advanced cirrhosis before and after liver transplantation.

Authors:  A Helmy
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

4.  Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: a human in vivo study.

Authors:  Jonathan M DiFabio; Tommaso Gori; George Thomas; Sean Jedrzkiewicz; John D Parker
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

5.  Can venous occlusion plethysmography be used to measure high rates of arterial inflow?

Authors:  Rachel E Wood; Ian B Stewart
Journal:  Eur J Appl Physiol       Date:  2009-09-23       Impact factor: 3.078

6.  Methotrexate modulates the kinetics of adenosine in humans in vivo.

Authors:  N P Riksen; P Barrera; P H H van den Broek; P L C M van Riel; P Smits; G A Rongen
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

7.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

8.  Quantitative aspects of the inhibition by N(G)-monomethyl-L-arginine of responses to endothelium-dependent vasodilators in human forearm vasculature.

Authors:  M Dawes; P J Chowienczyk; J M Ritter
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

9.  Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.

Authors:  K Swaminathan; J Davies; J George; N S Rajendra; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2008-03-18       Impact factor: 10.122

10.  Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels.

Authors:  Hironobu Minami; Takanori Yasu; Tatsuya Tagawa; Ken Yamakawa; Shinichiro Ueda
Journal:  Eur J Clin Pharmacol       Date:  2008-07-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.